Dr. Yael Porat BioGenCell CEO presents BioGenCell at the 2nd UK – Israel Regenerative Medicine Conference 2014
May 25, 2014
Dr. Yael Porat BioGenCell CEO presents BioGenCell’s strategy for producing autologous blood-derived cell therapy in a single day as part of the session ‘The Road to Clinical Translation – The viewpoint from Industry’ at the 2nd UK – Israel Regenerative Medicine Conference 2014 held in the Technion, Haifa, Israel.
US Patent 8709802 COM Method for using directing cells for specific stem/progenitor cell activation and differentiation – Issued April 2014
May 22, 2014
It’s All Possible (article in Hebrew)
November 29, 2011
An article in Hebrew about Dr. Yael Porat and her road to BioGenCell.
Dr. Porat to Participate in Global Entrepreneurship Week
November 11, 2011
During Global Entrepreneurship Week (13-20/11) BioGenCell’s CEO, Dr. Yael Porat, will give a talk about her career and her entrepreneurial ventures, most notably BioGenCell.
Global Entrepreneurship Week is a worldwide movement of entrepreneurial people, with millions unleashing their enterprising talents and turning their ideas into reality. Global Entrepreneurship Week 2011 will address the concerns and anxieties of budding entrepreneurs; enabling many more people to create new opportunities and successful ventures that will continue to flourish all year round.
For more information, please visit http://www.gew.org.il.
Remarkable Safety and Efficacy Results for Animal Model Trials
October 30, 2011
BioGenCell has conclusively proven the concept behind its state-of-the-art technology platform and its greater efficiency in terms of cost, time-of-production and ease-of-use compared to existing solutions. Based on the remarkable safety and efficacy results of its animal model trials, the company is now gearing up to start the clinical trials for BGC101. The product, which is manufactured from stem cells extracted from the patient’s own blood, is designed to treat blood vessel insufficiency that causes multiple organ failures in diabetic patients.
In the proof-of-concept trials that showed a high safety profile, the product proved its potency by significantly regenerating blood perfusion, promoting natural blood vessel formation and regenerating blood supply to the ischemic legs. Using accepted animal models for Critical Limb Ischemia (CLI) batches from healthy donors and diabetic patients were tested to assess efficacy, safety, dosing levels and bio-distribution, as performed by a GLP certified lab in adherence with OECD Principles of GLP guidelines.
Stem Cell Pioneers
June 15, 2010
Read Stem Cell Pioneers